Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Curr Opin Infect Dis ; 34(3): 217-227, 2021 06 01.
Article in English | MEDLINE | ID: covidwho-1200896

ABSTRACT

PURPOSE OF REVIEW: Central and peripheral nervous system manifestations of coronavirus disease 2019 (COVID-19) have been frequently reported and may cause significant morbidity and mortality. This review details the latest evidence on the neuropathogenesis and neurologic complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. RECENT FINDINGS: Commonly reported neurologic complications include toxic-metabolic encephalopathy, acute cerebrovascular disorders, seizures, and anoxic-brain injury. These complications represent secondary injury due to COVID-19 related hypoxia, sepsis, hypercoagulability, or hyperinflammation. Postinfectious complications, such as encephalitis, postinfectious demyelination, and Guillain-Barré syndrome have been reported, but are rare. Recent reports of persistent neurocognitive symptoms highlight the possibility of lasting impairment. SUMMARY: Although some neurologic complications should be treated with standard practices, further investigations are still needed to determine the optimal treatment of COVID-related neurologic complications, such as ischemic stroke. Entering into the next phase of the pandemic, investigations into the long-term neurologic and cognitive impacts of SARS-CoV-2 infection will be needed. Clinicians must have a high clinical suspicion for both acute and chronic neurologic complications among COVID-19 patients.


Subject(s)
COVID-19/complications , Nervous System Diseases/virology , Humans
2.
Cleve Clin J Med ; 87(12): 729-734, 2020 11 23.
Article in English | MEDLINE | ID: covidwho-732763

ABSTRACT

Patients with COVID-19 have a fairly high risk of neurologic complications, including encephalopathy, stroke, central nervous system infection, seizures, and neuromuscular diseases. Many report losing their senses of smell and taste, and many survivors report lingering neurocognitive impairment. The diagnosis and treatment of these complications does not differ from that in other patients, although sophisticated testing may not be readily available for a patient in intensive care and respiratory isolation. Clinicians should therefore be alert to these complications.


Subject(s)
COVID-19 , Central Nervous System Diseases , Neuromuscular Diseases , SARS-CoV-2 , Seizures , Stroke , COVID-19/complications , COVID-19/physiopathology , COVID-19/psychology , Central Nervous System Diseases/etiology , Central Nervous System Diseases/therapy , Cerebrospinal Fluid/virology , Diagnosis, Differential , Electroencephalography/methods , Humans , Magnetic Resonance Imaging/methods , Neuromuscular Diseases/etiology , Neuromuscular Diseases/therapy , Patient Care Management/methods , SARS-CoV-2/isolation & purification , SARS-CoV-2/pathogenicity , Seizures/etiology , Seizures/therapy , Stroke/etiology , Stroke/therapy , Symptom Assessment/methods
SELECTION OF CITATIONS
SEARCH DETAIL